Please assess the completion status of the following clinical trial:

Trial Title: [11C]Acetate PET in Patients With Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 and older, of any ethnic group~* Spanish-speaking patients will be eligible~* Histological diagnosis of glioma or~* Brain MR imaging suggestive of a glioma or 2HG \> 2mM by MR spectroscopy in patients who have not had a surgical procedure to establish the diagnosis.~* Karnofsky Performance status \> 70%~* Negative serum pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control~* Patient able and willing to provide informed consent~Exclusion Criteria:~* Patient or legal parent/guardian unable to provide informed consent~* Psychiatric or addictive disorders that preclude obtaining informed consent~* Karnofsky Performance status \< 70%~* NYHA class III and IV congestive heart failure~* Unstable angina~* Pregnant or lactating women~* Women of childbearing potential who refuse a pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [11C]Acetate Brain Imaging (Type: EXPERIMENTAL): \[11C\]Acetate will be administered The patient will have one intravenous line placed prior to \[11C\]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which \[11C\]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).